COVID-19 studies for: C19 studies:  HC QHC Q Vitamin DVitamin D IvermectinIVM LY-CoVLY REGN-COV2REGN RemdesivirRMD

Source   PDF   Share   Tweet
See all 143 studies
10/11
Inconc.
Late treatment study
Sili et al., medRxiv, doi:10.1101/2020.10.09.20209775 (Preprint) (not included in the study count)
Factors associated with progression to critical illness in 28 days among COVID-19 patients: results from a tertiary care hospital in Istanbul, Turkey
Analysis of hospitalized patients in Turkey showing HC Q was given to 99.2% of patients and the incidence of critical illness was lower than most studies. Authors note "whether HC Q administration lowered the rates of critical illness development is beyond the scope of this study." There is no comparison with a control group.
Source   PDF   Share   Tweet
See all 143 studies
Please send us corrections, updates, or comments.
Submit